Novavax (NVAX) Releases Promising Data on NanoFlu Vaccine, Prompting Upgrade at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices rise 2% as US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Citi Upgrades Novavax (NVAX) to Buy
March 1, 2018 8:42 AM ESTCiti upgraded Novavax (NASDAQ: NVAX) from Neutral to Buy with a price target of $3.50 (from $2.75).
Analyst Joel Beatty is more positive on the company noting he views the Phase 1/2 top-line data results for NanoFlu favorably. Combining the results with his improving... More
Novavax (NVAX) PT Raised to $3.50 at Ladenburg Thalmann
March 1, 2018 6:40 AM ESTLadenburg Thalmann raised its price target on Novavax (NASDAQ: NVAX) to $3.50 (from $2.50) while maintaining a Buy rating.
... MoreNovavax (NVAX) PT Raised to $2.50 at Piper Jaffray
March 1, 2018 1:53 AM ESTPiper Jaffray raised its price target on Novavax (NASDAQ: NVAX) to $2.50 (from $1.50) while maintaining a Neutral rating.
... MoreAfter-Hours Stock Movers 02/28: (NVAX) (DDD) (QEP) Higher; (PTLA) (BOX) (MNST) Lower (more...)
February 28, 2018 5:56 PM ESTToday's After-Hours Movers
Novavax, Inc., (Nasdaq: NVAX) 24% HIGHER; announced positive top-line results from its Phase 1/2 clinical trial in older adults of its NanoFlu recombinant influenza vaccine, which includes its proprietary Matrix-M adjuvant, compared to the leading licensed egg-based, high-dose influenza vaccine for older adults (IIV3-HD).
Portola Pharma (NASDAQ: PTLA) 23.2% LOWER; reported Q4 EPS of ($1.41), $0.05 better than the analyst estimate of ($1.46). Collaboration and License revenue for the quarter came in at $9.8 million versus the consensus estimate of $6.2 million. Provides... More
Novavax (NVAX) Says NanoFlu Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine
February 28, 2018 4:16 PM ESTNovavax, Inc., (Nasdaq: NVAX) today announced positive top-line results from its Phase 1/2 clinical trial in older adults of its NanoFlu recombinant influenza vaccine, which includes its proprietary Matrix-M(TM) adjuvant, compared to the leading licensed egg-based, high-dose influenza vaccine for older adults (IIV3-HD).
... More
Novavax (NVAX) Phase 1/2 Trial of NanoFlu Showed Improved Immune Responses
February 28, 2018 4:14 PM ESTNovavax, Inc., (Nasdaq: NVAX) today announced positive top-line results from its Phase 1/2 clinical trial in older adults of its NanoFlu recombinant influenza vaccine, which includes its proprietary Matrix-M adjuvant, compared to the leading licensed egg-based, high-dose influenza vaccine for older adults (IIV3-HD).
Key findings from the... More
